<DOC>
	<DOCNO>NCT00069017</DOCNO>
	<brief_summary>To compare , preliminary analysis , effect MEDI-522 versus placebo 6 month disease activity ( ACR20 ) progression structural joint damage .</brief_summary>
	<brief_title>Effects MEDI-522 On Disease Activity Progression Joint Damage Patients With Active Rheumatoid Arthritis Suboptimally Responding Methotrexate</brief_title>
	<detailed_description>To compare , preliminary analysis , effect subcutaneously administer MEDI-522 versus placebo 6 month disease activity progression structural joint damage patient rheumatoid arthritis ( RA ) , active disease despite ongoing treatment methotrexate ( MTX ) without hydroxychloroquine ( HCQ ) and/or sulfasalazine ( SSZ ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients must meet following criterion : 1 . Age great equal 18 ( reach 18th birthday later ) time first dose study drug 2 . Written inform consent obtain patient 3 . Sexually active female , unless surgically sterile least one year postmenopausal , must use effective method avoid pregnancy ( include oral , transdermal , injectable , implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 21 day prior first dose study drug , must agree continue use precaution 3 month last dose study drug . Cessation birth control point discuss responsible physician . 4 . A diagnosis RA define American College Rheumatology ( ACR ) criterion , currently active , defined presence least 6 swollen 6 tender joint involve hand , wrist , elbow , knee , ankle , foot CRP and/or ESR &gt; Upper Limits Normal ( ULN ) . 5 . Treatment stable dose level frequency methotrexate least 8 week prior study randomization . The patient may also take hydroxychloroquine and/or sulfasalazine concurrently methotrexate . These drug must also stable dose level frequency least 8 week prior randomization . Patients currently receive treatment stable dos nonsteroidal antiinflammatory drug ( NSAIDs ) , include COX2 inhibitor , prednisone ( less equal 10 mg/day ) permit continue medication . Analgesics , include acetaminophen , talwin , propoxyphene , tramadol hydrochloride , codeine codeine acetaminophen , hydrocodone , oxycontin , related medication , also permit . All drug must stable dose level frequency least 4 week prior study randomization . 6 . Prior randomization ( must within 21 day first administration study drug ) , follow : WBC ≥ 3,800/mm³ ; platelet count ≥140,000/mm³ ; AST , ALT , BUN , creatinine &lt; 1.5 x ULN ; stool negative occult blood ; thyroxine ( T4 ) within normal limit . ( Patients elevate T4 free T4 TSH level within normal limit may eligible review MedImmune medical monitor . ) 7 . Willing forego form experimental treatment study Study Day 364 8 . Able willing complete assessment questionnaire . 9 . Willing participate study Study Day 413 . Exclusion Criteria Patients must none following : 1 . Severe active RA , opinion investigator currently require alternative form therapy 2 . Acute illness start study 3 . Evidence significant active infection , fever great equal 38.0°C ( 100.5°F ) 4 . Known suspected infection human immunodeficiency virus ( HIV ) evidence clinically significant immune deficiency 5 . Evidence active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection , positive HBsAg positive antihepatitis C antibody 6 . Insulindependent diabetes mellitus recentonset unstable 7 . Evidence active latent tuberculosis , may include positive PPD skin test result ( great equal 10 mm induration ) , unless appropriate INH prophylaxis tuberculosis previously give ; chest Xray possibly consistent tuberculosis ; household contact patient active tuberculosis 8 . A medical history evidence clinically important chronic infection , recurrent ( 3 ) infection past 6 month require antibiotic , infection past month require systemic antibiotic 9 . Receipt investigational drug therapy , except MEDI522 , within 3 month prior study randomization ( use license agent indication list package insert permit ) 10 . Current past therapy antiTNF biologic antagonist include etanercept , infliximab , adalimumab 11 . Current therapy cyclosporin A , leflunomide , cyclophosphamide , azathioprine , gold salt , dpenicillamine , mycophenylate mofetil , minocycline anakinra . These drug must discontinue least 4 week prior study randomization . 12 . Prednisone equivalent &gt; 10 mg per day orally 8 week study randomization . Intraarticular , periarticular , form parenteral injection corticosteroid also permit 8 week prior study randomization . 13 . History allergic disease reaction likely exacerbate component MEDI522 14 . History gastrointestinal bleeding ( i.e. , stool positive occult blood overt bleed ) within previous 6 month 15 . Known bleed disorder significant risk clinically important abnormal bleeding due anticoagulant therapy warfarin heparin 16 . Elective surgery plan study period Study Day 413 17 . Cardiovascular disease unstable , recentonset angina , angina increase frequency severity , recent myocardial infarction ( within past 1 year without definitive corrective surgery coronary bypass graft angioplasty ) 18 . Neurological disease , multiple sclerosis , previous stroke , clinically significant cerebrovascular disease , form organic brain disease clinically significant 19 . Pulmonary , hepatic , renal , hematological disease unstable progressive , clinically severe 20 . Pregnancy ( female , unless surgically sterile least one year postmenopausal , must negative urine pregnancy test Study Day 0 , prior dose ) 21 . Nursing mother 22 . History alcohol drug abuse within past 2 year 23 . Evidence physical examination rheumatoid type vasculitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>